TheEdgeResearch
Home / Stocks / HALO

Halozyme Therapeutics, Inc. (HALO)

NASDAQ Healthcare Biotechnology
$77.08 ▲ +1.66%
Market Cap
$9.14B
Sector
Healthcare
Industry
Biotechnology
Beta
0.84
52-Wk Range
55.64-82.26
CEO
Helen I. Torley
Country
US
Currency
USD

Halozyme Therapeutics, Inc. is a biopharmaceutical company headquartered in San Diego, California, with operations spanning the United States, Switzerland, Ireland, Belgium, Japan, and other international markets. At its core is the proprietary ENHANZE drug delivery platform, which utilizes a patented recombinant human hyaluronidase enzyme (rHuPH20). This innovative technology significantly enhances the subcutaneous (under-the-skin) administration of a diverse range of injectable medicines. This includes complex biologics such as monoclonal antibodies, various other therapeutic molecules, smal…

Open full interactive analysis & DCF →